The table below shows Harmony Biosciences Holdings, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$215.39M
$239.46M
$200.49M
$184.73M
$186.04M
$172.81M
Cost of revenue
$44.51M
$59.65M
$38.15M
$31.99M
$42.78M
$32.14M
Gross profit
$170.88M
$179.81M
$162.34M
$152.74M
$143.26M
$140.67M
R&D
$69.38M
$54.96M
$50.16M
$34.54M
$25.39M
$63.58M
HRMY annual revenue (10-K history)
Harmony Biosciences Holdings, Inc. reported annual revenue of $868.45M for fiscal year 2025. That is up 21.5% from $714.73M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $6.00M (FY 2019) to $868.45M. Figures come from the company's audited annual reports as filed with the SEC.